Trillium Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics

TRIL 20.74

+1.0%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: semi_infinite	1/22/2019 12:14:13 PM
	Read Replies (1) of 294

anti CD47 potential issue with susceptibility to infections in NIH murine models. "Our data indicates that increased susceptibility to viral infections could be a significant side effect of these therapeutics. Additional data to define how those therapeutics impact CD47-SIRPa vs. thrombospondin-1-CD47 signaling in NK cells is required. " https://www.frontiersin.org/articles/10.3389/fimmu.2018.02985/full

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next